Listed biotech company Mesoblast says it is seeing positive signs for the use of its stem cell therapy in treating critically ill COVID-19 patients.
The company said 83 per cent of ventilator-dependent patients with a high risk of mortality who received its stem cell treatment have survived during early compassionate usage in New York's Mount Sinai hospital.
Loading...
Carrie LaFrenz is a senior journalist covering retail/consumer goods. She previously covered healthcare/biotech. Carrie has won multiple awards for her journalism including financial journalist of the year from The National Press Club. Connect with Carrie on Twitter. Email Carrie at carrie.lafrenz@afr.com
